View Post

Novel Approaches Push the Envelope in HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Jessica Hergert From: Developments in antibody-drug conjugates (ADCs), TKIs, and neoadjuvant interventions are improving outcomes for patients with early- and advanced-stage HER2-positive breast cancer, said Douglas K. Marks, MD, adding that investigational approaches could expand the treatment armamentarium even further. “For the treating oncologists, the options to offer patients who previously had a very poor prognosis are becoming …

View Post

Drug to Replace Chemotherapy May Reshape Cancer Care

In In The News by Barbara Jacoby

By: Kanoko Matsuyama From: * Promising treatment may reach far more breast cancer patients * Daiichi drug may outsell Roche’s Herceptin, spark dealmaking A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer …